210 related articles for article (PubMed ID: 7655890)
1. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ
Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.
Burn DJ; Sawle GV; Brooks DJ
J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173
[TBL] [Abstract][Full Text] [Related]
3. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
4. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
5. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
6. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
7. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
[TBL] [Abstract][Full Text] [Related]
8. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
10. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
11. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
[TBL] [Abstract][Full Text] [Related]
12. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration.
Goto S; Hirano A; Matsumoto S
Neurology; 1990 Jul; 40(7):1051-6. PubMed ID: 2192300
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy.
Rinne JO; Burn DJ; Mathias CJ; Quinn NP; Marsden CD; Brooks DJ
Ann Neurol; 1995 May; 37(5):568-73. PubMed ID: 7755350
[TBL] [Abstract][Full Text] [Related]
14. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
15. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease.
Eidelberg D; Takikawa S; Moeller JR; Dhawan V; Redington K; Chaly T; Robeson W; Dahl JR; Margouleff D; Fazzini E
Ann Neurol; 1993 May; 33(5):518-27. PubMed ID: 8498828
[TBL] [Abstract][Full Text] [Related]
16. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
18. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
19. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study.
Perani D; Bressi S; Testa D; Grassi F; Cortelli P; Gentrini S; Savoiardo M; Caraceni T; Fazio F
Arch Neurol; 1995 Feb; 52(2):179-85. PubMed ID: 7848128
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
